VACC
Price:
$5
Market Cap:
$43.89M
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in precl...[Read more]
Industry
Biotechnology
IPO Date
2021-04-30
Stock Exchange
NASDAQ
Ticker
VACC
According to Vaccitech plc’s latest financial reports and current stock price. The company's current ROE is -34.39%. This represents a change of 301.44% compared to the average of -8.57% of the last 4 quarters.
The mean historical ROE of Vaccitech plc over the last ten years is 16.59%. The current -34.39% ROE has changed -307.26% with respect to the historical average. Over the past ten years (40 quarters), VACC's ROE was at its highest in in the March 2021 quarter at 28.75%. The ROE was at its lowest in in the June 2023 quarter at -10.96%.
Average
16.59%
Median
2.20%
Minimum
-39.27%
Maximum
92.73%
Discovering the peaks and valleys of Vaccitech plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 92.73%
Minimum Annual Increase = -1885.50%
Minimum Annual ROE = -39.27%
Year | ROE | Change |
---|---|---|
2023 | -39.27% | -1885.50% |
2022 | 2.20% | -110.90% |
2021 | -20.17% | -142.50% |
2020 | 47.47% | -48.82% |
The current ROE of Vaccitech plc (VACC) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-19.08%
5-year avg
16.59%
10-year avg
16.59%
Vaccitech plc’s ROE is greater than Molecular Partners AG (-39.16%), greater than MediciNova, Inc. (-20.70%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), less than Champions Oncology, Inc. (66.22%), greater than Cyteir Therapeutics, Inc. (-9.44%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Talaris Therapeutics, Inc. (-16.04%), greater than Adicet Bio, Inc. (-53.85%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Vor Biopharma Inc. (-101.14%), greater than Tyra Biosciences, Inc. (-25.14%), greater than Third Harmonic Bio, Inc. (-14.46%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than Revolution Medicines, Inc. (-33.67%), greater than Design Therapeutics, Inc. (-18.01%), greater than Achilles Therapeutics plc (-54.57%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than Magenta Therapeutics, Inc. (-14.27%), greater than Graphite Bio, Inc. (-57.96%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than Instil Bio, Inc. (-37.44%), less than Spero Therapeutics, Inc. (3.36%), greater than Assembly Biosciences, Inc. (-121.46%),
Company | ROE | Market cap |
---|---|---|
-39.16% | $195.74M | |
-20.70% | $101.53M | |
-184.40% | $39.16M | |
66.22% | $111.60M | |
-9.44% | $108.71M | |
-26.83% | $2.80B | |
-16.04% | $116.44M | |
-53.85% | $73.46M | |
-26.54% | $710.38M | |
-101.14% | $60.35M | |
-25.14% | $749.88M | |
-14.46% | $468.61M | |
-42.45% | $263.30M | |
-54.45% | $596.14M | |
-33.67% | $8.07B | |
-18.01% | $353.88M | |
-54.57% | $47.27M | |
-8.54% | $8.20M | |
-14.27% | $42.44M | |
-57.96% | $185.19M | |
-41.34% | $84.91M | |
-37.44% | $138.61M | |
3.36% | $51.11M | |
-121.46% | $95.47M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vaccitech plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vaccitech plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Vaccitech plc's ROE?
How is the ROE calculated for Vaccitech plc (VACC)?
What is the highest ROE for Vaccitech plc (VACC)?
What is the 3-year average ROE for Vaccitech plc (VACC)?
What is the 5-year average ROE for Vaccitech plc (VACC)?
How does the current ROE for Vaccitech plc (VACC) compare to its historical average?